Vendors stopped naming the compound

If you shop for GLP-1 compounds, you've probably watched a listing change under you. What said "Tirzepatide" a couple of years ago said "GLP-2" by 2024, and now says something like "pp-2T" or "X-2" or a house brand with a letter stuck on the end.

It's deliberate, and it's not about you. Three pressures landed on this market at roughly the same time. The FDA started scraping vendor sites for compound names and escalated from warning letters to warehouse raids. Payment processors screen on keywords, so a listing with the real compound name on it triggers an account freeze far faster than "pp-2T" does. And Lilly and Novo began suing distributors, which is considerably easier to do when the compound name is sitting right there on the product page to quote in the filing.

So the name moved, it lives in the certificate of analysis now, if it lives anywhere at all.

What changed for us as buyers is smaller than it sounds and more serious than it looks. The COA used to be the confirmation. Now it's the only identification. A listing that said "GLP-2" at least pointed you in a direction. "pp-2T" points nowhere. If the COA is in-house only, missing, or vague about what the compound actually is, there's no backup and the listing won't save you. That was always a red flag. In this naming environment it's a dealbreaker.

We wrote up the full version here, including how the labels shifted year by year: https://peptidepricelab.com/plain-language/why-vendors-hide-glp-compound-names/

What's the strangest house name you've run into? Some of them are genuinely hard to decode and we'd like to see what's out there.